Obesity Is an Independent Predictor of Poor Survival in Metastatic Breast Cancer: Retrospective Analysis of a Patient Cohort Whose Treatment Included High-Dose Chemotherapy and Autologous Stem Cell Support. (6th July 2011)

• Record Type: Journal Article
• Authors: von Drygalski, A.; Tran, T. B.; Messer, K.; Pu, M.; Corringham, S.; Nelson, C.; Ball, E. D.
• Other Names: Montemurro Filippo Academic Editor.
• Is Part Of: International journal of breast cancer. Volume 2011(2011)
• Publication Date: 2011-07-06
• Subjects: Breast -- Cancer -- Periodicals; Periodicals; Breast Neoplasms; Breast -- Cancer; Periodicals; Periodicals; 616.99449
• DOI: 10.4061/2011/523276
• Languages: English
• ISSNs: 2090-3170

Abstract

Abstract : The purpose of the study was to identify predictors of long-term survival in metastatic breast cancer (MBC). A cohort of 96 patients, who received high-dose chemotherapy with autologous stem cell support (HD-ASCT) as part of their treatment, was analyzed. Percent long-term survival at 10 years was 24.5% (CI 17.2–34.9%) when metastasis was diagnosed and 14.4% (CI 8.7–23.9%) when MBC was diagnosed. Survival was impacted significantly by body mass index (BMI). Median overall survival from initial diagnosis or from time of metastasis for patients with BMIs ≤30 and >30 (obese) was 7.1 (CI 4.4–8.7) and 3.2 years (2.41–6.75), respectively, or 3.2 or 2.3 years (allP = 0.02 ). Also, obesity was the only independent patient-related predictor of time to metastasis and of survival. While obesity is linked with poor outcomes in earlier stages of breast cancer, this has not been previously reported for MBC.